Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000416646

Medchemexpress LLC Pristimerin (Celastrol methyl ester) | 1258-84-0 | MFCD01711331 | 464.64 | 50 MG
SDP

Catalog No. 5000416646
Encompass_Preferred

Pristimerin is a potent and reversible monoacylglycerol lipase (MGL) inhibitor with an IC50 of 93 nM. It inhibits MGL rapidly, reversibly, and non-competitively, possibly through a polar interaction with Cys208. Pristimerin also inhibits HFLS-RA and HUVEC cell viability in a dose- and time-dependent manner, and decreases VEGF-induced autophosphorylation of VEGFR2, attenuating the VEGFR2-mediated signaling pathway. Furthermore, Pristimerin inhibits inflammation and tumor angiogenesis, reducing vessel density in synovial membrane tissues of inflamed joints and lowering the expression of pro-angiogenic factors like TNF-α, Ang-1, and MMP-9 in sera.

  • Potent and reversible monoacylglycerol lipase (MGL) inhibitor.
  • Inhibits HFLS-RA and HUVEC cell viability.
  • Attenuates VEGFR2-mediated signaling pathway.
  • Inhibits inflammation and tumor angiogenesis.

Catalog No. 50-004-16646 Supplier Medchemexpress LLC Supplier No. HYN193750MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Pristimerin is a potent and reversible monoacylglycerol lipase (MGL) inhibitor with an IC50 of 93 nM. It inhibits MGL rapidly, reversibly, and non-competitively, possibly through a polar interaction with Cys208. Pristimerin also inhibits HFLS-RA and HUVEC cell viability in a dose- and time-dependent manner, and decreases VEGF-induced autophosphorylation of VEGFR2, attenuating the VEGFR2-mediated signaling pathway. Furthermore, Pristimerin inhibits inflammation and tumor angiogenesis, reducing vessel density in synovial membrane tissues of inflamed joints and lowering the expression of pro-angiogenic factors like TNF-α, Ang-1, and MMP-9 in sera.

  • Potent and reversible monoacylglycerol lipase (MGL) inhibitor.
  • Inhibits HFLS-RA and HUVEC cell viability.
  • Attenuates VEGFR2-mediated signaling pathway.
  • Inhibits inflammation and tumor angiogenesis.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.